American Society of Cataract and Refractive Surgery

Lehigh Valley Eye Center, a OCLI Vision practice, Welcomes New Glaucoma Specialist to Their Expanding Team of Eye Care Professionals

Retrieved on: 
Monday, September 19, 2022
American Academy, American Board of Ophthalmology, American Board of Commissioners for Foreign Missions, Suite, Retina, Refractive surgery, MD, Association for Research in Vision and Ophthalmology, Research, Cornell University, American Glaucoma Society, Glaucoma, Optometry, Cornea, American Society of Cataract and Refractive Surgery, Lehigh Valley, Neuro-ophthalmology, ASC, Growth, Economics, Information technology, Internal medicine, Cataract, Patient, Louisiana State University, Technology, Surgeon, Association, Marketing, American Academy of Ophthalmology, University, SVP, Hospital, New York University, Ophthalmology

BETHLEHEM, Pa., Sept. 19, 2022 /PRNewswire-PRWeb/ -- OCLI Vision is excited to welcome Bonny Lee, MD, a fellowship-trained, board-certified glaucoma specialist to its growing team of eye care professionals at the Lehigh Valley Eye Center, an OCLI Vision practice in Bethlehem. The eye care clinic is located at 3535 High Point Boulevard, Suite 800 Bethlehem, PA 18017.

Key Points: 
  • OCLI Vision is excited to welcome Bonny Lee, MD, a fellowship-trained, board-certified glaucoma specialist to its growing team of eye care professionals at the Lehigh Valley Eye Center, an OCLI Vision practice in Bethlehem.
  • BETHLEHEM, Pa., Sept. 19, 2022 /PRNewswire-PRWeb/ -- OCLI Vision is excited to welcome Bonny Lee, MD, a fellowship-trained, board-certified glaucoma specialist to its growing team of eye care professionals at the Lehigh Valley Eye Center, an OCLI Vision practice in Bethlehem.
  • "I'm grateful to be joining the world-class team of eye care professionals in the Lehigh Valley," stated Dr. Lee.
  • The practices of OCLI Vision offer eye care services at locations throughout Connecticut, New Jersey, New York, Pennsylvania, and West Virginia.

Johnson & Johnson Vision: Surgical Vision Announces New Data and Sustainability Activities at European Society of Cataract and Refractive Surgeons Congress

Retrieved on: 
Tuesday, September 6, 2022
Zero, Health care, Sustainability, Forest, Mentorship, Pain, Natural Resources, Congress, Johnson & Johnson Vision, Cataract, Surgeon, CO2, 2021 Essex County Council election, Patient, INT, Human factors and ergonomics, Family, Johnson & Johnson, Climate change, Industry, Efficiency, Aqueous humour, Region, Cataract surgery, Mico, Medtech, Toric, Medical device, LinkedIn, Intraocular lens, Electricity, Use, Health, Ophthalmology, American Society of Cataract and Refractive Surgery, CEST, Presbyopia, Life, Fine chemical, Pharmaceutical industry, Flour, Renewable energy, Medicine, Facebook, Woman

19 September 2022, 14:14 17:00

Key Points: 
  • 19 September 2022, 14:14 17:00
    About Johnson & Johnson Vision: Surgical Vision*
    At Johnson & Johnson Vision: Surgical Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health worldwide.
  • *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Medical Ltd, and the affiliates of both.
  • *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Medical Ltd, and the affiliates of both.
  • **The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision, and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.

STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems

Retrieved on: 
Wednesday, August 10, 2022
Other Consumer, Women, Parenting, Men, Pharmaceutical, Optical, TV and Radio, Family, Music, Medical Devices, Consumer, LGBTQ+, Entertainment, Film & Motion Pictures, Surgery, Health, Advertising, Communications, Celebrity, U.S. Securities and Exchange Commission, Lens (anatomy), CEO, Dioptre, Dry eye syndrome, Prevalence, Security (finance), Marketing, Education, STAAR, Ophthalmology, Night vision, Marriage, MD, Jonas, Iris, Glaucoma, Astigmatism, Multimedia, Lens, Retinal implant, EVO, American Society of Cataract and Refractive Surgery, Inflammation, Technology, Perseverance, Partnership, Refractive surgery, Cornea, Literature, Myopia, Intraocular lens, ICL, Awareness, Nave, Social media, Goal, FDA, Quality, Cataract, Hans Hassle, Society, Review, Eye, Glasses, NASDAQ, Intention, Vision disorder, Nursing, ASCRS, Telescopic sight, Medical device, Borosilicate glass, Life, LASIK, Patient

Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction.

Key Points: 
  • Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction.
  • He decided to undergo the EVO procedure, which involved adding a small, flexible lens in both eyes to correct his distance vision.
  • Joe Jonas was a great candidate for EVO and we are thrilled to have helped him achieve his vision goals.
  • Joe Jonas needed EVO lenses below -5.0 diopters, so he was a great candidate for EVO, said Scott D. Barnes, MD, Chief Medical Officer of STAAR Surgical.

Surgical Care Coalition and Over 100 Medical Organizations Urge Congress to Stop Pending Medicare Cuts That Will Impact Millions of Seniors

Retrieved on: 
Monday, August 1, 2022
Surgeon, Congress, Cataract, Physician, Health, Global Initiative for Emergency and Essential Surgical Care, Solution, PAYGO, CMS, Medicare Sustainable Growth Rate, Refractive surgery, Multimedia, American Society of Cataract and Refractive Surgery, Quality of life, Policy, MBA, Calendar, Centers for Medicare & Medicaid Services, Ecosystem, MD, Patient, MPFS, Anesthesiology, Letter, Center, Medicare, FACS, Health insurance

The Centers for Medicare & Medicaid Services (CMS) recently proposed a nearly 4.5% cut to the Medicare conversion factor, a key element for calculating Medicare payments.

Key Points: 
  • The Centers for Medicare & Medicaid Services (CMS) recently proposed a nearly 4.5% cut to the Medicare conversion factor, a key element for calculating Medicare payments.
  • When combined with the pending 4% Pay-As-You-Go (PAYGO) cut, surgical care faces a nearly 8.5% cut next year.
  • As medical costs reach record highs, the proposed cuts reflect an unsustainable Medicare payment system that is out-of-touch with the needs of millions of Americans.
  • The Surgical Care Coalition advocates for access to quality surgical care for all Americans.

Patient care under continued threat in proposed Medicare Physician Fee Schedule

Retrieved on: 
Thursday, July 7, 2022
Health, Cataract, Surgeon, Centers for Medicare & Medicaid Services, Patient, Refractive surgery, DO, Breast cancer, CMS, FASA, Society, Center, Ophthalmology, Association, Face, MBA, Woman, Risk, Environment, American Society of Cataract and Refractive Surgery, American Society of Breast Surgeons, American Society of Anesthesiologists, Advocacy, Quality of life, Global Initiative for Emergency and Essential Surgical Care, Congress, Health policy, FACS, ASA, Medicare, Neurology, American Academy of Ophthalmology, Health insurance, Dentistry, Pharmaceutical industry, Anesthesiology, MD

WASHINGTON, July 7, 2022 /PRNewswire/ -- The proposed Medicare Physician Fee Schedule for calendar year 2023 (CY2023) released today by the Centers for Medicare & Medicaid Services (CMS) once again jeopardizes seniors' access to critical treatments and procedures, according to the Surgical Care Coalition. 

Key Points: 
  • WASHINGTON, July 7, 2022 /PRNewswire/ -- The proposed Medicare Physician Fee Schedule for calendar year 2023 (CY2023) released today by the Centers for Medicare & Medicaid Services (CMS) once again jeopardizes seniors' access to critical treatments and procedures, according to the Surgical Care Coalition.
  • As surgical care faces another round of proposed cuts, it's clear that these cuts on top of the sequester cuts threaten patient care and are unsustainable for the long term.
  • "Today's proposed rule underscores the continued disinvestment in patient care, and the Surgical Care Coalition urges Congress to immediately stop these cuts to protect patients and work toward finding a long-term solution that promotes quality care and investment."
  • Unfortunately, CMS's proposed Medicare Physician Fee Schedule for 2023 poses an even greater risk than in years past to patient access to these and other life-altering interventions."

Big Win for Patients: Aetna Drops Prior Authorization for Most Cataract Surgeries

Retrieved on: 
Thursday, June 30, 2022
Cataract, Aetna, Ministry of Interior and Federal Affairs (Somalia), Refraction, Centers for Medicare & Medicaid Services, Patient, CEO, Falls, American Academy, Legislation, Dementia, Medicare Advantage, Center, Multimedia, MA, Mark (given name), Policy, SAN, Risk, American Society of Cataract and Refractive Surgery, Organization, Icare, Quality of life, House, Leadership, United States House of Representatives, American Academy of Ophthalmology, Medicare, Safety, Physician, Society, Program, Senior, Health insurance, Pharmaceutical industry, Ophthalmology, Academy, MD

SAN FRANCISCO, June 30, 2022 /PRNewswire/ -- After a year of sustained advocacy from the ophthalmology community, Aetna announced this week that it will no longer require pre-approval for cataract surgeries starting July 1, 2022, except for people enrolled in Medicare Advantage in Florida and Georgia*. While it remains unclear why these two states are excluded from the rollback, the American Academy of Ophthalmology will continue its effort to protect all patients from abusive prior authorization policies.

Key Points: 
  • While it remains unclear why these two states are excluded from the rollback, the American Academy of Ophthalmology will continue its effort to protect all patients from abusive prior authorization policies.
  • Last July, the nation's third-largest health insurer instituted a sweeping and unprecedented new policy requiring pre-approval for all physician-prescribed cataractsurgeries.
  • The Academy estimates that 10,000 to 20,000 Aetna beneficiaries had their cataract surgery unnecessarily delayed in the month of July alone.
  • *Cataract surgery for Florida and Georgia MA beneficiaries will still require prior authorization through iCare.

Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

Retrieved on: 
Wednesday, June 29, 2022
Trustee, Cataract, Retinal, Patient, Refractive surgery, CEO, Annual general meeting, DME, Ophthalmology, Retina, Disease, ASCRS, Pain, Inflammation, U.S. FDA, American Society of Cataract and Refractive Surgery, Dexamethasone, Minimisation, Safety, Society, Geisel School of Medicine, Pharmaceutical industry, Pecten oculi

In the completed Phase 2 SKYGGN study, once-daily OCS-01 successfully met its primary endpoint demonstrating superior efficacy and safety vs vehicle (placebo) in the treatment of inflammation and pain following cataract surgery.

Key Points: 
  • In the completed Phase 2 SKYGGN study, once-daily OCS-01 successfully met its primary endpoint demonstrating superior efficacy and safety vs vehicle (placebo) in the treatment of inflammation and pain following cataract surgery.
  • Positive data from that trial was presented at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Annual Meeting.
  • Oculis subsequently held a positive end-of-Phase 2 meeting with U.S. FDA which enabled the start of the Phase 3 OPTIMIZE trial.
  • Treatment of inflammation and pain following ocular surgery is another indication being pursued for OCS-01, following the commencement in November 2021 of the Phase 3 DIAMOND trial investigating OCS-01 in patients with DME.

Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

Retrieved on: 
Wednesday, June 29, 2022
Trustee, FDA, Cataract, Retinal, Patient, Refractive surgery, CEO, Annual general meeting, DME, Ophthalmology, Retina, Disease, ASCRS, Pain, Inflammation, American Society of Cataract and Refractive Surgery, Dexamethasone, Minimisation, Safety, Society, Geisel School of Medicine, Pharmaceutical industry, Pecten oculi

In the completed Phase 2 SKYGGN study, once-daily OCS-01successfully met its primary endpoint demonstrating superior efficacy and safety vs vehicle (placebo) in the treatment of inflammation and pain following cataract surgery.

Key Points: 
  • In the completed Phase 2 SKYGGN study, once-daily OCS-01successfully met its primary endpoint demonstrating superior efficacy and safety vs vehicle (placebo) in the treatment of inflammation and pain following cataract surgery.
  • Positive data from that trial was presented at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Annual Meeting.Oculis subsequently held a positive end-of-Phase 2 meeting with U.S. FDAwhich enabledthe start of the Phase 3 OPTIMIZE trial.
  • Treatment of inflammation and pain following ocular surgery is another indication being pursued for OCS-01, following the commencement in November 2021 of the Phase 3 DIAMOND trial investigating OCS-01 in patients with DME.
  • clinical professor of ophthalmology at New York University and Trustee of Dartmouth Medical School, said: Following cataract surgery, patients often need to self-administer eye drops several times a day to manage inflammation and pain.

SightMD Welcomes Marc G. Rubinstein, M.D. to their New York Team of Providers

Retrieved on: 
Wednesday, June 15, 2022
American Academy, SUNY Downstate Medical Center, State university system, American Board of Commissioners for Foreign Missions, American Society of Cataract and Refractive Surgery, Society, Brooklyn Hospital Center, American Academy of Ophthalmology, Refractive surgery, Cataract, Neuro-ophthalmology, Saint, Pediatric ophthalmology, Retina, Audiology, State, Patient, American Board of Ophthalmology, Health insurance, Growth, Ophthalmology, LASIK

HAUPPAUGE, N.Y., June 15, 2022 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Marc G. Rubinstein, M.D. to its expert team.

Key Points: 
  • is a dedicated ophthalmologist to join its growing team of over 80 providers in the New York Tri-state region.
  • HAUPPAUGE, N.Y., June 15, 2022 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Marc G. Rubinstein, M.D.
  • Dr. Rubinstein is a dedicated ophthalmologist that is based in New York and the Bronx, NY.
  • Sight Growth Partners is the administrative services provider for SightMD as well as SightMD Connecticut, SightMD New Jersey, and SightMD Pennsylvania.

Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 5, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Retinitis pigmentosa, University, Failure, Development, Toxicity, Liver disease, Safety, Eye, Allergic conjunctivitis, Risk, Annual report, American Society of Cataract and Refractive Surgery, Securities Exchange Act of 1934, SEC, CEO, Annual general meeting, Chronic cough, Investor, ASCRS, Twitter, Biotechnology, Patient, Clinical trial, Retina, Inflammation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, New Drug Application, LinkedIn, Research, Conversation, Therapy, Cataract, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, NDA, Schirmer, Security (finance), Analysis, Systemic disease, RASP, Financial condition report, Growth, Duane syndrome, COVID-19, Part, Nasdaq, Result, Food, Refractive surgery, Review, Marketing, Society, Pharmaceutical industry, Ethanol, Ophthalmology, Facebook

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended March 31, 2022.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended March 31, 2022.
  • Aldeyra completed enrollment in the Phase 3 TRANQUILITY-2 Trial of 0.25% reproxalap ophthalmic solution in patients with dry eye disease.
  • Aldeyra is continuing to review data from the completed TRANQUILITY Trial to finalize analytical plans for the TRANQUILITY-2 results.
  • ET today to discuss recent corporate highlights and financial results for the quarter ended March 31, 2022.